Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;26(7):1337-1342.
doi: 10.1111/tbj.13762. Epub 2020 Jan 30.

Multigene panel testing results in patients with multiple breast cancer primaries

Jessica Corredor  1 , Ashley H Woodson  1 , Angelica Gutierrez Barrera  2 , Banu Arun  1   2
Affiliations

Multigene panel testing results in patients with multiple breast cancer primaries

Jessica Corredor et al. Breast J. 2020 Jul.

Abstract

Currently, the NCCN guidelines recommend testing of BRCA1 and BRCA2 for females with multiple breast primaries, if her first diagnosis was ≤50 years old. With the increase in uptake of multigene panels, testing for genes outside of BRCA1 and BRCA2 has become more prevalent. This study looked at a single institution's cohort of women with multiple primary breast cancers that underwent panel testing to determine the rates of pathogenic mutations in non-BRCA genes. The genetic testing results for each individual were reviewed, along with patient characteristics. Descriptive analysis and two-tailed Z tests were used to analyze the data. Out of 85 eligible women, 33 (38.8%) tested positive for a pathogenic mutation in a cancer predisposition gene: 9 BRCA1, 5 BRCA2, 5 ATM, 1 BARD1, 4 CHEK2, 1 MSH2, 1 MSH6, 2 PALB2, 1 PMS2, 1 PTEN and 3 TP53. Overall, 17.6% tested positive for a non-BRCA breast cancer predisposition gene. There was no difference in the age of first or second breast cancer diagnosis in comparison with genetic testing outcomes. This study found a high positive rate for all individuals with multiple breast cancers, regardless of age, for both BRCA1 and BRCA2 and non-BRCA genes. Future studies should investigate whether individuals with multiple breast cancer primaries that do not meet BRCA1 and BRCA2 testing criteria should undergo genetic testing, regardless of the age of diagnosis.

Keywords: breast cancer predisposition genes; genetics; multiple breast primaries; panel testing.

PubMed Disclaimer

References

REFERENCES

    1. Kollias J, Ellis I, Elston C, Blamey R. Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg. 2001;25(9):1117-1124.
    1. Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14(5):552-558.
    1. Kurian A, McClure L, Esther J, Horn-Ross P, Ford J, Clarke C. Second primary breast cancer occurrence according to hormone receptor status. JNCI. 2009;101(15):1058-1065.
    1. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:1-11.
    1. Molina-Montes E, Perez-Nevot B, Pollan M, Sánchez-Cantalejo E, Espín J, Sánchez MJ. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast. 2014;23:721-742.